Dawson James Lowers ADMA Biologics (NASDAQ:ADMA) to Neutral

Share on StockTwits

Dawson James cut shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a neutral rating in a research note issued to investors on Monday morning, FlyOnTheWall reports. Dawson James currently has $4.00 price objective on the biotechnology company’s stock. Dawson James also issued estimates for ADMA Biologics’ Q3 2019 earnings at ($0.11) EPS, Q4 2019 earnings at $0.12 EPS, FY2019 earnings at ($0.56) EPS, Q1 2020 earnings at ($0.01) EPS, FY2020 earnings at ($0.02) EPS, FY2021 earnings at $0.18 EPS, FY2022 earnings at $0.78 EPS and FY2023 earnings at $1.36 EPS.

ADMA has been the topic of a number of other reports. HC Wainwright set a $13.00 price target on shares of ADMA Biologics and gave the company a buy rating in a research report on Thursday, May 23rd. Oppenheimer set a $14.00 price target on shares of ADMA Biologics and gave the company a buy rating in a research report on Tuesday, June 25th. Finally, Jefferies Financial Group began coverage on shares of ADMA Biologics in a research report on Tuesday, June 4th. They set a buy rating and a $8.00 price target on the stock. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $10.17.

ADMA opened at $3.90 on Monday. The company’s 50 day simple moving average is $3.73 and its 200 day simple moving average is $4.03. The company has a debt-to-equity ratio of 1.79, a current ratio of 10.26 and a quick ratio of 2.39. ADMA Biologics has a 1 year low of $2.08 and a 1 year high of $6.96.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. The business had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $4.36 million. ADMA Biologics had a negative net margin of 323.54% and a negative return on equity of 214.26%. As a group, sell-side analysts anticipate that ADMA Biologics will post -0.96 earnings per share for the current fiscal year.

In other ADMA Biologics news, major shareholder Biotest Divestiture Trust sold 5,813,954 shares of ADMA Biologics stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $3.75, for a total transaction of $21,802,327.50. Following the transaction, the insider now directly owns 4,295,580 shares of the company’s stock, valued at $16,108,425. The sale was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive purchased 4,000,000 shares of ADMA Biologics stock in a transaction on Tuesday, May 21st. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $16,000,000.00. The disclosure for this purchase can be found here. Insiders own 15.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Private Advisors LLC acquired a new position in ADMA Biologics during the second quarter valued at approximately $41,000. Parametric Portfolio Associates LLC purchased a new stake in shares of ADMA Biologics during the second quarter valued at approximately $49,000. Tower Research Capital LLC TRC raised its stake in shares of ADMA Biologics by 13,268.0% during the second quarter. Tower Research Capital LLC TRC now owns 13,368 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 13,268 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of ADMA Biologics during the fourth quarter valued at approximately $34,000. Finally, Citadel Advisors LLC raised its stake in shares of ADMA Biologics by 96.3% during the second quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock valued at $86,000 after purchasing an additional 10,887 shares during the period. 38.82% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Further Reading: How can investors benefit from after-hours trading?

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.